drugset / Trial / NCT05299697
A Study of TG103 Injection in Overweight or Obesity
RandomizedParallel-groupSingle-blindTreatment
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase II study to evaluate efficacy, safety, pharmacokinetics characteristics and immunogenicity of two dose levels of TG103 injection, a GLP-1 receptor agonist, in the management of overweight or obesity, to support dose selection for further development.
Timeline
- Start
- 2022-05-20
- Primary completion
- 2023-06-30
- Completion
- 2023-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TG103 | Protein / enzyme biologic | 15 mg | Subcutaneous |
| Subject | TG103 | Protein / enzyme biologic | 22.5 mg | Subcutaneous |